Lesley Cole
Primary Care · Douglasville, GANPI 1750026522
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 30.1% of the total. Reporting peaked in 2024 at $973 and has fallen 54.3% since, to $444 in 2025.
Across 98 payments — averaging $23.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$681
- Lilly USA, LLC$332
- Novo Nordisk$239
- Collegium Pharmaceutical, Inc.$233
- Amgen$136
- GSK$101
- plus $542 from 15 others
What the payments were for
- Food & beverage$2,265100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $681 |
| Lilly USA, LLC | 15 | $332 |
| Novo Nordisk | 15 | $239 |
| Collegium Pharmaceutical, Inc. | 13 | $233 |
| Amgen | 7 | $136 |
| GSK | 6 | $101 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $85 |
| Boehringer Ingelheim | 3 | $63 |
| Antares Pharma, Inc. | 3 | $60 |
| Kowa Pharmaceuticals America, Inc. | 4 | $51 |
| Idorsia Pharmaceuticals US Inc | 3 | $50 |
| Exact Sciences | 3 | $42 |
| Sumitomo Pharma America, Inc. | 1 | $38 |
| Tolmar, Inc. | 2 | $29 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Protega Pharmaceutials Inc | 1 | $12 |
| Virtus Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,265 in reported general payments places this provider in the 80th percentile of 235 primary care providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $68,081 |
| MounjaroTirzepatide | 53 | $62,759 |
| JardianceEmpagliflozin | 29 | $36,022 |
| EliquisApixaban | 21 | $27,258 |
| MyrbetriqMirabegron | 30 | $25,521 |
| JanuviaSitagliptin Phosphate | 16 | $23,126 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $17,062 |
| LinzessLinaclotide | 13 | $7,675 |
| BrilintaTicagrelor | 11 | $4,621 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 90 | $2,413 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $2,000 |
| Gabapentin | 114 | $1,700 |
| Losartan Potassium | 118 | $1,441 |
| Amlodipine Besylate | 204 | $1,273 |
| Atorvastatin Calcium | 161 | $1,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $239 | $68,08149 claims |
| Lilly USA, LLCMounjaro | $332 | $62,75953 claims |
| Boehringer IngelheimJardiance | $63 | $36,02229 claims |
| GSKTrelegy Ellipta | $101 | $17,06226 claims |
| AstraZenecaBrilinta | $681 | $4,62111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 235 primary care providers in Georgia.
Other primary care in Douglasville
- Pamela TurkDouglas$15K
- Morgan JonesLawrenceville$14K
- Jessi HaleColumbus$13K
- Meredith CarrAugusta$12K
- Ashtyn ZaryckiSavannah$12K
- Zanetta BryantNewnan$11K
- Hannah CummingsSuwanee$9K
- Michelle LadewigGainesville$7K
- Lucia OcanoviciuCanton$7K
- Sarah NewGrovetown$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.